Policy & Regulation
Sobi presents phase 3 gout study results for pozdeutinurad
29 October 2026 - Swedish biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) on Thursday reported late-breaking data from the phase 3 REDUCE-2 study showing that investigational ...
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
29 October 2026 - Biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) said on Thursday that it has signed a binding exclusive negotiation agreement with Japanese clinical-stage biotech...
Formation Bio establishes USD600m debut fund for drug development
29 October 2026 - Formation Bio, a New York-based, AI-native pharmaceutical company, announced on Wednesday the Formation Bio Drug Development Accelerator Fund with USD600m in capital commitments.This...
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
29 October 2026 - Chinese pharmaceutical company Ascletis Pharma Inc (HKEX:1672) on Wednesday reported positive topline results from its US Phase II study evaluating ASC30, an oral small molecule GLP-...
MetaVia announces presentation of DA-1726 Phase 1 data at Precision Liver Symposium
28 October 2026 - Biotechnology company MetaVia Inc (Nasdaq: MTVA) announced on Wednesday that it will present Phase 1 clinical trial data for DA-1726, its investigational dual GLP-1 and glucagon rece...
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
28 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Wednesday announced positive topline results from its Phase 3 LiGeR-HN1 trial, showing that petosemtamab combined with pembroliz...